1.Gross, S. J., Pletcher, B. A., and Monaghan, K. G. Carrier screening in individuals of Ashkenazi Jewish descent. Genet Med 2008;10(1):54–56.
2.Botkin, J. R. Assessing the new criteria for newborn screening. Health Matrix Clevel 2009;19(1):163–186.
3.McGowan, M. L., Cho, D., and Sharp, R. R. The changing landscape of carrier screening: expanding technology and options? Health Matrix Clevel 2013;23(1):15–33.
4.Prior, T. W. Next-generation carrier screening: are we ready? Genome Med 2014;6(8):62.
5.World Health Organization Human Genetics Programme. Proposed international guidelines on ethical issues in medical genetics and genetic services (part I). Rev Derecho Genoma Hum 1998;(8):219–223.
6.World Health Organization Human Genetics Programme. Proposed international guidelines on ethical issues in medical genetics and genetic services (part II). Rev Derecho Genoma Hum 1998;(9):239–251.
7.Prior, T. W. Carrier screening for spinal muscular atrophy. Genet Med 2008;10(11):840–842.
8.Kaback, M. M. Screening and prevention in Tay-Sachs disease: origins, update, and impact. Adv Genet 2001;44:253–265.
9.ACOG. ACOG Committee Opinion No. 432: Spinal muscular atrophy. Obstet Gynecol 2009;113(5):1194–1196.
10.ACOG. ACOG Committee Opinion No. 442: Preconception and prenatal carrier screening for genetic diseases in individuals of Eastern European Jewish descent. Obstet Gynecol 2009;114(4):950–953.
11.Cystic Fibrosis Centre, H. f. S. C., CFCHSC Cystic Fibrosis Mutation Database 2011.
12.Williamson, R. Universal community carrier screening for cystic fibrosis? Nat Genet 1993;3(3):195–201.
13.Southern, K. W., Munck, A., Pollitt, R., et al. A survey of newborn screening for cystic fibrosis in Europe. J Cyst Fibros 2007;6(1):57–65.
14.Metcalfe, S. A. Carrier screening in preconception consultation in primary care. J Community Genet 2012;3(3):193–203.
15.ACOG ACMG, A. C. o. O. a. G. A. C. o. M. G. Preconception and Prenatal Carrier Screening for Cystic Fibrosis. Clinical and Laboratory Guidelines 2001. Washington, DC: American College of Obstetricians and Gynecologists.
16.Strom, C. M., Crossley, B., Buller-Buerkle, A., et al. Cystic fibrosis testing 8 years on: lessons learned from carrier screening and sequencing analysis. Genet Med 2011;13(2):166–172.
17.ACOG. ACOG Committee Opinion No. 486: Update on carrier screening for cystic fibrosis. Obstet Gynecol 2011;117(4):1028–1031.
18.Angastiniotis, M. and Modell, B. Global epidemiology of hemoglobin disorders. Ann N Y Acad Sci 1998;850:251–269.
19.ACOG. ACOG Practice Bulletin No. 78: Hemoglobinopathies in pregnancy. Obstet Gynecol 2007;109(1):229–237.
20.Cao, A., Rosatelli, M. C., and Galanello, R. Control of beta-thalassaemia by carrier screening, genetic counselling and prenatal diagnosis: the Sardinian experience. Ciba Found Symp 1996;197:137–151; discussion 151–135.
21.Mitchell, J. J., Capua, A., Clow, C., and Scriver, C. R. Twenty-year outcome analysis of genetic screening programs for Tay-Sachs and beta-thalassemia disease carriers in high schools. Am J Hum Genet 1996;59(4):793–798.
22.Scriver, C. R. Community genetics and dignity in diversity in the Quebec Network of Genetic Medicine. Community Genet 2006;9(3):142–152.
23.Cousens, N. E., Gaff, C. L., Metcalfe, S. A., and Delatycki, M. B. Carrier screening for beta-thalassaemia: a review of international practice. Eur J Hum Genet 2010;18(10):1077–1083.
24.Edwards, J. G., Feldman, G., Goldberg, J., et al. Expanded carrier screening in reproductive medicine-points to consider: a joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society for Maternal-Fetal Medicine. Obstet Gynecol 2015;125(3):653–662.
25.Kingsmore, S. Comprehensive carrier screening and molecular diagnostic testing for recessive childhood diseases. PLoS Curr 2012;e4f9877ab9878ffa9879.
26.Lazarin, G. A., Haque, I. S., Nazareth, S., et al. An empirical estimate of carrier frequencies for 400+ causal Mendelian variants: results from an ethnically diverse clinical sample of 23,453 individuals. Genet Med 2013;15(3):178–186.
27.Srinivasan, B. S., Evans, E. A., Flannick, J., et al. A universal carrier test for the long tail of Mendelian disease. Reprod Biomed Online 2010;21(4):537–551.
28.Cho, D., McGowan, M. L., Metcalfe, J., and Sharp, R. R. Expanded carrier screening in reproductive healthcare: perspectives from genetics professionals. Hum Reprod 2013;28(6):1725–1730.
29.Desai, A. N. and Jere, A. Next-generation sequencing: ready for the clinics? Clin Genet 2012;81(6):503–510.
30.Lazarin, G. A. and Haque, I. S. Expanded carrier screening: A review of early implementation and literature. Semin Perinatol 2016;40(1):29–34.
31.Tanner, A. K., Valencia, C. A., Rhodenizer, D., et al. Development and performance of a comprehensive targeted sequencing assay for pan-ethnic screening of carrier status. J Mol Diagn 2014;16(3):350–360.
32.Bell, C. J., Dinwiddie, D. L., Miller, N. A., et al. Carrier testing for severe childhood recessive diseases by next-generation sequencing. Sci Transl Med 2011;3(65):65ra64.
33.Brezina, P. R., Benner, A., Rechitsky, S., et al. Single-gene testing combined with single nucleotide polymorphism microarray preimplantation genetic diagnosis for aneuploidy: a novel approach in optimizing pregnancy outcome. Fertility and Sterility 2011;95(5):1786.e1785–1786.e1788.
34.ACOG. ACOG Committee Opinion No. 691: Carrier screening for genetic conditions. Obstet Gynecol 2017;129:e41–55.